Written and Reviewed by Team Pharmacally
Breakthrough Immunization Covers Five Major Serogroups, Simplifying Protection against Deadly Infections
The U.S. Food and Drug Administration (FDA) has approved Penmenvy, an innovative vaccine aimed at preventing invasive meningococcal disease (IMD) caused by serogroups A, B, C, W, and Y. This significant approval represents the first instance of a single vaccine providing protection against all five major meningococcal serogroups, filling an important void in global vaccination initiatives.
Key Features of Serogroups
Serogroups A, B, C, W, and Y represent various groups of Neisseria meningitidis, the bacterium responsible for meningococcal disease, including meningitis and septicemia. These serogroups are categorized according to variations in the structure of their capsular polysaccharides, which are protective outer layers that assist the bacteria in evading the immune system.
Serogroup A: This group has historically been linked to significant epidemics, especially in sub-Saharan Africa, often referred to as the “meningitis belt.” Vaccination efforts have led to a notable decrease in its occurrence.
Serogroup B: It is a primary cause of meningococcal disease in wealthier nations, such as the U.S. and Europe. Developing vaccines for this serogroup is challenging because its capsule closely resembles human neural tissue.
Serogroup C: This serogroup has been a major contributor to outbreaks globally, particularly before the advent of widespread vaccination. The introduction of vaccines has significantly lowered the number of cases.
Serogroup W: Known for causing more severe illness, this serogroup can present with unusual symptoms, including gastrointestinal problems. It has been increasingly reported in certain areas.
Serogroup Y: This group is more commonly linked to pneumonia and bloodstream infections, especially among older adults.
Understanding the Threat of Meningococcal Disease
Meningococcal disease was first noted during an outbreak in Geneva, Switzerland, in 1805. Later, it was identified that invasive meningococcal disease is caused by the bacterium Neisseria meningitidis. This serious illness can lead to meningitis, which is the inflammation of the brain and spinal cord, and septicemia, or blood poisoning. Symptoms can develop quickly, and the fatality rates can be as high as 10–15% even with treatment. The disease is particularly alarming due to how swiftly it can lead to death in previously healthy individuals, the potential for large outbreaks through airborne transmission, and hyper endemic situations, all of which contribute to significant public concern.
Historically, vaccines targeting meningococcal strains have been split into two categories:
Quadrivalent vaccines (covering serogroups A, C, W, Y), such as Menveo and MenQuadfi.
Serogroup B vaccines, including Bexsero and Trumenba.
Until now, individuals seeking comprehensive protection required multiple vaccinations.
However, now penmenvy’s approval streamlines this process, offering broad coverage in a single formulation.
Penmenvy: A New Era in Prevention
GSK’s pentavalent MenABCWY vaccine, Penmenvy, is created by merging antigenic components from their Menveo (MenACWY) and Bexsero (MenB) vaccines, aiming to protect against five meningococcal serogroups: A, B, C, W-135, and Y.
Antigenic Components
Menveo Contribution (Quadrivalent ACWY): Each serogroup (A, C, W-135, and Y) is created through the fermentation of Neisseria meningitidis strains. The polysaccharides undergo purification, chemical activation, and are then conjugated to CRM197, a non-toxic mutant of the diphtheria toxin carrier protein, to boost immunogenicity.
Bexsero Contribution (MenB): This vaccine includes three antigens: Factor H binding protein (fHbp) from subfamily B, Neisserial adhesin A (NadA), and Neisserial Heparin Binding Antigen (NHBA).
Combination Strategy:
MenACWY Conjugates: The four conjugated polysaccharides (A, C, W-135, and Y) are mixed in a solution.
MenB Proteins: The three recombinant proteins (fHbp, NadA, NHBA) are combined with aluminium hydroxide as an adjuvant, much like Bexsero.
Parallel Production:
MenACWY: The polysaccharides are fermented, purified, conjugated with CRM197, and then combined.
MenB Proteins: Recombinant proteins are produced, purified, and then adsorbed onto aluminium hydroxide. Final Formulation: The components are mixed in precise ratios to ensure even distribution of the antigens and proper dispersion of the adjuvant.
Clinical Trial Results
The approval was backed by encouraging outcomes from two key Phase III clinical trials: NCT04502693 and NCT04707391. These studies assessed the vaccine’s safety, tolerability, and immune response in more than 4,800 participants aged 10 to 25 years. The safety data indicated that the vaccine’s safety profile aligns with that of GSK’s licensed meningococcal vaccines.
The clinical trial identified by NCT04502693 is a Phase III, randomized, controlled, observer-blind study. It aimed to assess the effectiveness, immunogenicity, and safety of GSK’s meningococcal Group B vaccine (Bexsero) alongside the combined ABCWY vaccine in healthy adolescents and young adults. The results were promising, showing that the MenABCWY combination vaccine achieved all primary endpoints. The vaccine was well-tolerated, exhibiting a safety profile similar to that of Bexsero and Menveo, and demonstrated statistical non-inferiority when compared to these vaccines in individuals aged 10-25 years.
Participants in the study (NCT04707391) received either two doses of the MenABCWY vaccine given six months apart or a single dose of the MenACWY-CRM vaccine. The main goal was to show that the MenABCWY vaccine was not inferior to the MenACWY-CRM vaccine in producing a four-fold increase in human serum bactericidal antibody (hSBA) levels against serogroups ACWY one month after vaccination. Secondary endpoints included the percentage of participants with hSBA titers exceeding the lower limit of quantitation against serogroups ACWY and vaccine antigen-specific serogroup B (MenB) indicator strains
The study found that the immune responses triggered by the MenABCWY vaccine against serogroups ACWY were comparable to those produced by the MenACWY-CRM vaccine. Furthermore, after receiving two doses of the MenABCWY vaccine, a notable percentage of participants showed hSBA titers exceeding the lower limit of quantitation against MenB indicator strains.
Public Health Implications
1. Reduction in Disease Burden: The launch of Penmenvy is set to greatly decrease the occurrence of meningococcal disease, a significant contributor to illness and death, particularly among children, adolescents, and young adults. By targeting five serogroups with a single vaccine, it provides extensive protection, potentially averting thousands of cases each year.
2. Global Immunization Strategies: Increased Coverage in High-Risk Areas: Numerous African nations (notably the “meningitis belt”), along with certain regions in Asia and Europe, frequently face outbreaks of meningococcal disease. A pentavalent vaccine will be extremely advantageous in these areas, where vaccine access is often restricted. Integration into Routine Vaccination Schedules: Adding Penmenvy to national immunization programs, particularly for infants, adolescents, and travellers to endemic regions, could enhance efforts to control the disease’s spread more effectively than the current limited vaccine options.
3. Herd Immunity and Community Protection: Widespread vaccination against various serogroups of N. meningitidis can foster herd immunity. This means that even those who are unvaccinated can benefit from a decrease in the transmission of the bacteria within the community, providing indirect protection, especially for individuals unable to receive vaccines due to health issues.
4. Improved Surveillance and Early Detection: With the extensive coverage of Penmenvy, there will be a greater need for strong surveillance systems. Keeping track of vaccine effectiveness and the epidemiology of invasive meningococcal disease in real time will be essential for public health authorities to effectively respond to potential outbreaks.
5. Economic Impact: Reduced Healthcare Costs: By preventing meningococcal disease, which can be expensive to treat, especially in critical care situations, this vaccine has the potential to decrease the overall healthcare burden, including hospital stays, treatments, and long-term care for those who survive. Cost-effectiveness: In countries with a high incidence of the disease, the cost-effectiveness of the pentavalent vaccine will play a crucial role in its acceptance, as it could lead to significant savings by reducing the number of IMD cases.
6. Challenges in Implementation:
Vaccine Access and Equity: Although the pentavalent vaccine could significantly change the landscape, its distribution needs to be fair. It is essential to ensure that all populations, especially those in low- and middle-income countries, can access Penmenvy to effectively control the disease globally.
Vaccine Hesitancy: As with many vaccines, there may be some reluctance to adopt it in certain groups. Public health initiatives will be vital to foster trust in the vaccine and address any concerns.
Conclusion
The FDA’s approval of Penmenvy marks a significant advancement in the fight against invasive meningococcal disease. This pentavalent vaccine aims to fill the void left by serogroup-specific vaccines, offering improved global immunity as meningococcal strains continue to change and outbreaks remain a concern. As the rollout commences, continuous monitoring will be essential to guarantee its safety and effectiveness, reinforcing Penmenvy’s position as a key element in preventive healthcare.
References
1. Cabellos C, Pelegrín I, Benavent E, et al, Invasive Meningococcal Disease: What We Should Know, Before It Comes Back. Open Forum Infect Dis. 2019 Feb 7; 6(3):ofz059. Doi: 10.1093/ofid/ofz059. PMID: 30949522; PMCID: PMC6440684
2. Nolan T, Bhusal C, Beran J, et al, Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial. Lancet Infect Dis. 2024 Dec 5:S1473-3099(24)00667-4. Doi: 10.1016/S1473-3099(24)00667-4. Epub ahead of print. PMID: 39647494
3. Terry Nolan, Chiranjiwi Bhusal, Jiří Beran, et al, 4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young Adults, Open Forum Infectious Diseases, Volume 11, Issue 11, November 2024, ofae638,https://doi.org/10.1093/ofid/ofae638
4. Sherman AC, Stephens DS. Serogroup A meningococcal conjugate vaccines: building sustainable and equitable vaccine strategies. Expert Rev Vaccines. 2020 May; 19(5):455-463. Doi: 10.1080/14760584.2020.1760097. Epub 2020 Apr 29. PMID: 32321332; PMCID: PMC8214415
5. Meningococcal Disease, CDC, US Centre for disease control and prevention
6. Stephen I. Pelton, The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines, Journal of Adolescent Health, Volume 59, Issue 2, Supplement, 2016, Pages S3-S11, https://doi.org/10.1016/j.jadohealth.2016.04.012
7. Shin T, Wells CR, Shoukat A, et al. Quadrivalent Conjugate Vaccine and Invasive Meningococcal Disease in US Adolescents and Young Adults. JAMA Netw Open.2024; 7(11):e2443551. doi:10.1001/jamanetworkopen.2024.43551
8. Penmenvy, GSK’s 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY, Stock Exchange Announcement, GSK, 15 February 2025
9. Highlights of prescribing information, PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) for injectable suspension, GSK Vaccines
10. FDA Approves Penmenvy (meningococcal groups A, B, C, W, and Y vaccine) for Prevention of Invasive Meningococcal Disease Caused by Serogroups A, B, C, W, and Y, Drugs.com. 15 February 2025
11. Bekkat-Berkani, Rafik et al., Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB, Journal of Infection, Volume 85, Issue 5, 481 – 491
12. Shah HA, Jutlla G, Herrera-Restrepo O, et al, Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States. Pharmacoeconomics. 2025 Mar; 43(3):311-329. Doi: 10.1007/s40273-024-01439-y. Epub 2024 Nov 25. PMID: 39585581; PMCID: PMC11825582.
Add a Comment